B+
Bull case
25%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
LENZ
LENZ TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Early repeat purchasing, wider prescribing access, and international licensing could support a larger VIZZ franchise if product revenue accelerates. LENZ reported $220.0 million of cash, equivalents, and marketable securities at June 30, 2026, although that balance is now dated.
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29 · BMO.
What can break
Commercial adoption and repeat-use estimates are early and may not persist across larger patient cohorts. [#SEC-8K-2026-08-11]
Momentum
5
Value
57
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.55 · Bull $5.20 · Bear $1.60Analysis 2026-10-25; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum5 · Δ7d +1.3
Value57 · Δ7d -0.1
Sentiment67 · Δ7d +7.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29 · BMO.
- • Sentiment remains the lead driver in the composite, 7D delta +7.4.
Contradictions & invalidation
- • Commercial adoption and repeat-use estimates are early and may not persist across larger patient cohorts. [#SEC-8K-2026-08-11]
- • Competing presbyopia drops and lower-priced alternatives may limit VIZZ uptake; LENZ cautions that its product has not been evaluated head-to-head against Vuity. [#10-K-2026-03-24] 2025 Form 10-K.
- • Q2 product revenue of $1.7 million was small relative to $39.4 million of SG&A, and the $5.5 million total revenue included license payments that should not be extrapolated as recurring product demand.
Catalyst clock
2026-10-29 · BMO
October 29 results test VIZZ launch acceleration
Lead driver: Sentiment · See AI snapshot
Momentum
5
8% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
+2.5
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.6
Sentiment
67
45% active weight
Current posture
7d trendImproving
Δ7d
+7.4
Δ21d
-20.2
Why this grade
Composite grade B. Momentum 5.5 / Value 56.8 / Sentiment 67.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.55
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$98.97M
Beta
0.58
Shares Out
31.42M
P/E (TTM) · Derived
-1.1
P/S (TTM)
29.47
P/FCF (TTM) · Derived
-0.85
Rev YoY
+9.7%
EPS YoY
+91.5%
Gross Margin
+90.1%
Op Margin
-631.7%
Net Debt
-$291.53M
Current Ratio
13.55
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data